- Home
- EHLD vs SABS Comparison
EHLD vs SABS Comparison
Compare EHLD & SABS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EHLD
- SABS
- Stock Information
- Founded
- EHLD 2024
- SABS 2014
- Country
- EHLD Greece
- SABS United States
- Employees
- EHLD N/A
- SABS N/A
- Industry
- EHLD
- SABS Biotechnology: Pharmaceutical Preparations
- Sector
- EHLD
- SABS Health Care
- Exchange
- EHLD NYSE
- SABS Nasdaq
- Market Cap
- EHLD 17.2M
- SABS 15.8M
- IPO Year
- EHLD N/A
- SABS N/A
- Fundamental
- Price
- EHLD $7.82
- SABS $2.55
- Analyst Decision
- EHLD
- SABS Strong Buy
- Analyst Count
- EHLD 0
- SABS 5
- Target Price
- EHLD N/A
- SABS $11.60
- AVG Volume (30 Days)
- EHLD 14.9K
- SABS 4.3M
- Earning Date
- EHLD 08-15-2025
- SABS 08-07-2025
- Dividend Yield
- EHLD 7.16%
- SABS N/A
- EPS Growth
- EHLD N/A
- SABS N/A
- EPS
- EHLD 4.74
- SABS N/A
- Revenue
- EHLD $14,687,504.00
- SABS $377,835.00
- Revenue This Year
- EHLD N/A
- SABS N/A
- Revenue Next Year
- EHLD N/A
- SABS N/A
- P/E Ratio
- EHLD $1.65
- SABS N/A
- Revenue Growth
- EHLD N/A
- SABS N/A
- 52 Week Low
- EHLD $3.83
- SABS $1.00
- 52 Week High
- EHLD $12.80
- SABS $6.60
- Technical
- Relative Strength Index (RSI)
- EHLD N/A
- SABS 58.13
- Support Level
- EHLD N/A
- SABS $2.25
- Resistance Level
- EHLD N/A
- SABS $2.85
- Average True Range (ATR)
- EHLD 0.00
- SABS 0.60
- MACD
- EHLD 0.00
- SABS -0.01
- Stochastic Oscillator
- EHLD 0.00
- SABS 12.62
About EHLD EUROHOLDINGS LTD
Euroholdings Ltd is a provider of shipping transportation services. The company specializes in the ownership of vessels. The fleet of the company consists of containerships that transport container boxes providing scheduled service between ports.
About SABS SAB Biotherapeutics Inc.
SAB Biotherapeutics Inc is a clinical stage biopharmaceutical company focused on the development and commercialization of a portfolio of products from its proprietary immunotherapy platform to produce fully targeted human polyclonal antibodies, without using human plasma or serum. The company's novel DiversitAb platform enables the rapid production of large amounts of targeted human polyclonal antibodies, leveraging transchromosomic cattle (Tc Bovine) that have been genetically designed to produce human antibodies (immunoglobulin G) rather than bovine in response to an antigen. Animal antibodies have been made in rabbits, sheep and horses.